University of Cambridge > Talks.cam > Biophysical Seminars > Developing drugs for neurodegeneration and other diseases in academia, industry and in-between

Developing drugs for neurodegeneration and other diseases in academia, industry and in-between

Add to your list(s) Download to your calendar using vCal

If you have a question about this talk, please contact Patrick Flagmeier.

Over recent decades, medicinal chemists have proven to be very efficient at finding small molecules to modulate the activity of enzyme and receptor targets but this has not always led to the development of new drugs. Drawing on examples from industry, academia and the not-for-profit sector, ways in which this gap can be bridged will be explored. Firstly, the importance of expanding the range of druggable targets will be discussed using the example of RAD51 -BRCA2 protein-protein interaction inhibitors. Secondly, the challenge of identifying druggable targets to drive a reduction in the level of the misfolded proteins thought to cause many neurodegenerative diseases will be explored, using examples from the Alzheimer’s Research UK Cambridge Drug Discovery Institute.

This talk is part of the Biophysical Seminars series.

Tell a friend about this talk:

This talk is included in these lists:

Note that ex-directory lists are not shown.

 

© 2006-2018 Talks.cam, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity